Esperion Therapeutics, Inc.

Analysis for Ticker: ESPR

Esperion Therapeutics Inc is a pharmaceutical business that develops oral pills like NEXLETOL and NEXLIZET to help people lower their cholesterol by blocking an enzyme called ACLY. The company is effectively being liquidated through an acquisition by an investment firm called ARCHIMED for approximately 800,53$ million. The math is a disaster because the people in charge have spent months printing millions of new shares to pay themselves while the business burns cash. On 16/04/2026, the company revealed that the chief executive officer Sheldon L Koenig was paid 7,09$ million for one year of work, even as the stock price sat at a low 2,74$ in 03/2026. The management is asking for 7,0 million more shares to be added to their pay pool, which already holds 30,15 million shares ready to be handed out for free. The bleeding is absolute; the company has already mortgaged its future revenue from Japan and Europe to lenders, leaving almost nothing for the people who actually own the stock. The history of how this situation developed shows a consistent pattern of taking from the company to pay the leaders. In 2023, the business lost 209,2$ million, followed by a loss of 51,7$ million in 2024. To get more cash, they sold their future European royalties to a group called OMERS in 06/2024 for 304,7$ million. This deal means OMERS takes 100% of the money from Europe until they collect 517,9$ million. They also took a 150,0$ million loan from GLAS USA, Athyrium, and HCR. Because the company cannot afford to pay the interest in cash, it uses a trick called paid-in-kind interest at a rate of 11,75%, which simply adds the debt to the total balance every day.